Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05559996

Assessment of the Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause

Genitourinary Syndrome of Menopause Clinical Trial

Official title:
Assessment of the Efficacy of Multifractional Intercalated Hyaluronic Acid Injection for Genitourinary Syndrome of Menopause

Clinical Trial Summary

The vaginal wall consists of epithelium, lamina propria, muscularis and adventitia (1). The decrease in postmenopausal estrogen levels causes thinning of the vaginal wall thickness and the development of genitourinary menopause syndrome (GSM), which is characterized by vaginal dryness, burning, pruritus, urinary complaints and sexual discomfort (2). In the treatment of GSM symptomatology, there are many different non-hormonal treatment options such as vaginal topical agents and energy-based devices, as well as estrogen-based hormonal therapies (3). The main problem with non-hormonal treatments is the short-term resolution of vaginal atrophy and the lack of long-term results, while contraindications such as breast cancer history and unwillingness of the women to use hormones are problematic for estrogen-based treatments. Considering all these issues, there is a search for new therapeutic agents with long and high efficiency and safety profile in the treatment of GSM. Hyaluronic acid (HA) which is one of the main components of the extracellular matrix and has water-binding property that provides moisturizing and lubricating effect (4). Besides, it is also reported as the key to the process of tissue regeneration through inflammation, cellular migration and angiogenesis (5). For these reasons, it seems to be a promising treatment of GSM symptomatology. HA has many routes of administration, such as vaginal gels, ovules, and suppositories, and studies have shown that locally applied HA preparations have a short-term therapeutic effect on GSM symptoms (6). However, there is no consensus regarding HA efficacy due to heterogeneity of studies. Since it is an endogenous molecule, it can be thought that it will be more effective if it is injected directly into the epithelium rather than locally applied. The injectable form of multifractional intercalated cross-linked HA (MIC-HA) (Armonia®, Regenyal, Italy) is designed for the reinforcement of the extracellular matrix in the female genital area. We intend to investigate and objectively evaluate the efficacy of MIC-HA injection on GSM symptoms and sexual functions in postmenopausal women.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Genitourinary Syndrome of Menopause
  • Syndrome
Clinical Trial Details
NCT number NCT05559996
Study type Interventional
Source Maltepe University
Contact
Status Completed
Phase N/A
Start date April 1, 2021
Completion date November 1, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05812924 - A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause Phase 2
Completed NCT04535323 - Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer Phase 1
Completed NCT03331328 - MonaLisa Touch Randomized Double-Blind Placebo Controlled Study N/A
Recruiting NCT04746456 - Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
Withdrawn NCT04606550 - MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study N/A
Completed NCT04705883 - Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors Phase 4
Recruiting NCT05953090 - VALOR: Vaginal Atrophy & Long-term Observation of Recovery N/A
Active, not recruiting NCT04619485 - Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy N/A
Completed NCT04607798 - Multi-polar RF and PEMF for Treatment of Vulvovaginal Atrophy N/A
Recruiting NCT06124820 - RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections N/A
Completed NCT05561972 - The Ultrasonographic Assessment of Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause N/A
Recruiting NCT05571527 - Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause N/A
Recruiting NCT04677491 - Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders Phase 4
Not yet recruiting NCT06425978 - Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit Phase 4
Recruiting NCT05672901 - Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause N/A
Recruiting NCT03782480 - Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy Phase 3
Recruiting NCT06028009 - PRP Injections for Genitourinary Syndrome of Menopause N/A
Not yet recruiting NCT06007027 - Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors N/A
Terminated NCT03857893 - New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy N/A
Completed NCT05782920 - Management of Cancer Therapy Related Vulvovaginal Atrophy N/A